GlassScriptPhysician profile
Roger L Siddoway
NPI 1548240310
$2,186.29
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $279 · 2021: $834 · 2022: $560 · 2023: $64.50 · 2024: $24.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.82 | 2019-2024 | Linzess, Viberzi |
| Janssen Biotech, INC. | $333.55 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.54 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $108.05 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.84 | 2019-2022 | |
| Qol Medical, LLC | $85.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $71.64 | 2021-2022 | |
| Braintree Laboratories, INC. | $67.18 | 2019-2021 | |
| Genzyme Corporation | $65.76 | 2022 | |
| Alfasigma USA, INC. | $53.89 | 2020-2022 | |
| Shire North American Group INC | $50.81 | 2019 | |
| Pfizer INC. | $47.55 | 2019-2022 | |
| Allergan, INC. | $44.60 | 2019 | |
| Daiichi Sankyo INC. | $24.90 | 2021 | |
| Gilead Sciences, INC. | $24.44 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.12 | 2022 | |
| Amgen INC. | $17.87 | 2020 | |
| Ironwood Pharmaceuticals, INC | $16.91 | 2020 | |
| Ucb, INC. | $15.92 | 2019 | |
| Boston Scientific Corporation | $11.28 | 2019 | |
| Ambu INC. | $9.30 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$755.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Siddoway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.